Announced Tue, 30 Jun · 18:52 IST
Beryl Drugs closes trading window ahead of Q1 FY27 results
Compliance View source PDF
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+3.2%1-day move
₹22.20
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————+3.2-4.5-6.7+2.7+6.6+9.8-4.9———
Up moveDown movePending
AI summary
Beryl Drugs has closed its insider trading window for the quarter ended 30 June 2026. The closure is mandatory under SEBI insider trading rules and applies to directors, key managerial personnel, and other designated persons. They cannot buy or sell company shares until the window reopens after the unaudited financial results for the quarter are announced.
Likely market impact
Routine compliance filing. No direct stock impact expected, but signals that Q1 FY27 results are due shortly.